Company intelligence / Profile preview

Sigma-RBI

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

Sigma-RBI is a specialized brand within MilliporeSigma, the life science business of Merck KGaA, focused on providing high-quality reagents for neuroscience and signal transduction research. The entity was formed following the 1998 acquisition of Research Biochemicals International (RBI) by Sigma-Aldrich. It offers a comprehensive portfolio of neurochemicals, including agonists, antagonists, and inhibitors for various receptors and enzymes. These tools are widely used in academic and industrial laboratories to study complex biological processes and drug discovery. Sigma-RBI is known for its high standards of purity and its role as a key supplier in the global life sciences market.

Therapeutic areas: NeurologyOther
Modalities: Small moleculePeptides
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Sigma-RBI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sigma-RBI.

Explore the full profile